GlobalData on MSN18h
Viking reports data from X-linked adrenoleukodystrophy trialViking Therapeutics has announced positive results from its Phase Ib clinical trial of VK0214, a thyroid hormone receptor ...
HealthDay on MSN6h
Hematologic Cancer Develops in Some Patients Receiving Eli-CelHematologic cancer develops in some patients receiving lentiviral elivaldogene autotemcel (eli-cel) gene therapy for cerebral ...
Most boys treated with breakthrough gene therapy for a rare but deadly brain illness are faring well six years later, two new ...
Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...
The company’s recent Phase 1b trial of VK-0214, an oral therapy for the treatment of X-linked adrenoleukodystrophy (X-ALD), demonstrated significant reductions in very long chain fatty acids (VLCFAs), ...
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
GlobalData on MSN15h
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trialsWhilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...
Clario and PathAI partnered to offer an integrated solution for enhancing efficiency of gastrointestinal (GI) clinical trials ...
GlobalData on MSN20h
Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib studyChicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study, with the company to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback